UCB Bime maintains impressive efficacy in PsO at 4 years
At the recent AAD meeting, UCB presented its 4-year pooled data for Bimzelx in PsO and commented in a capital markets briefing. Bimzelx shows high maintenance levels with 88.0% PASI90 and 72.6% PASI100 after 4y at FDA approved dosing and clean safety. We see the consistent high PASI100 as differentiator vs. other IL17 drugs, and maintain our Accumulate/TP € 110.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.